Dexmedetomidine for electrical storm, repeated dangerous heart rhythms, in intensive care
Tests dexmedetomidine versus placebo in adults with electrical storm, repeated dangerous heart rhythms.
Key facts
- Who runs it
- Ottawa Heart Institute Research Corporation
- Where
- Rochester, United StatesSee the siteAlso in 1 other country, 1 site
- Trial code
- Registry title
- Study Evaluating Dexmedetomidine in the Acute Treatment of Electrical Storm
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 192 people, planned
- Started
- 8 May 2024
- Expected to end
- 1 Aug 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Dexmedetomidine
- Normal saline
- Record updated
- 7 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults in an intensive care unit with electrical storm. This means repeated dangerous fast heart rhythms from the lower heart chambers.
- Age
- Over 18 years.
- Sex
- All sexes can join.
- Disease stage
- Electrical storm (recurrent ventricular arrhythmias) needing admission to an intensive care unit.
- Earlier treatment
- People who received dexmedetomidine or clonidine in the 24 hours before randomization cannot join.
Main reasons for not taking part
- Severe shock lasting more than 30 minutes not caused by the heart rhythm problem, needing two or more blood pressure drugs, or SCAI class D or E cardiogenic shock.
- Cardiac arrest with no-flow and low-flow total time over 10 minutes before joining.
- Heart rhythm problem caused by a STEMI heart attack with signs of ongoing reduced blood flow.
- Slow heart rate under 40 beats per minute, or serious heart block (second degree Mobitz type 2 or greater) without a pacemaker.
- Pregnancy, or known allergy or intolerance to dexmedetomidine.
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- All patients admitted to an intensive care unit with electrical storm over the age of 18 years will be approached for enrollment
Who cannot take part
- Cardiac arrest(s) with a no-flow and low-flow total time of greater than 10 minutes prior to recruitment
- Patients who have received dexmedetomidine or clonidine during the 24 hours prior to randomization
- Refractory shock lasting for more than 30 minutes unrelated to ventricular arrhythmias (VAs), defined as requiring two or more vasopressors
- ST-segment elevation myocardial infarction (STEMI)-induced VA with signs of active ischemia
- Bradycardia with heart rate less than 40 beats per minute, bradycardia-induced ventricular tachyarrhythmia, second degree Mobitz type 2 or greater atrioventricular block in the absence of a pacemaker
- Known dexmedetomidine allergy or intolerance
- SCAI class D or E cardiogenic shock
- Pregnancy
- Inability to obtain consent from patient or substitute decision maker
Where in United States
Also in 1 other country, 1 site
- Mayo ClinicRochester, United StatesContact: Pietro Di Santo, MD PhDNot yet recruiting
About the trial
What the trial wants to find out
The objective of this study is to determine if there is a meaningful benefit to using the sedative medication dexmedetomidine in the acute treatment of patients with recurrent ventricular arrhythmias, known as electrical storm. This will be a multi-centre, double-blinded, placebo-controlled, randomized trial. Patients with electrical storm will be randomized to receive 48 to 72 hours of dexmedetomidine or placebo as part of their initial treatment in an intensive care unit.
The 2 groups in the trial
- DexmedetomidineExisting treatment, for comparison
Participants randomized to receive dexmedetomidine will be started at a dose of 0.3 mcg/kg/hr and titrated to a target dose of 1.0 mcg/kg/hr. Once the participant reaches their maximum tolerated dose (as decided by the blinded treating physician), they will continue treatment for 48 ± 6 hours. This will be followed by a weaning phase that will similarly be at the discretion of the treating physician.
- PlaceboPlacebo, for comparison
Participants randomized to receive placebo will be started on normal saline. In similar fashion to the active comparator, participants will be titrated to their maximal tolerated dose, continue treatment for 48 ± 6 hours, and be weaned at the discretion of the blinded treating physician.
Treatment: Normal saline
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Study Evaluating Dexmedetomidine in the Acute Treatment of Electrical Storm
- Plain-language title
- Dexmedetomidine for electrical storm, repeated dangerous heart rhythms, in intensive careGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 7 July 2026